Association for Molecular Pathology submits written comments to FDA on NGS regulation

The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular diagnostic professionals, submitted written comments on March 20 to the U.S. Food and Drug Administration (FDA) in response to the agency's request for feedback in association with its February 20, 2015 public workshop entitled, "Optimizing FDA's Regulatory Oversight of Next Generation Sequencing Diagnostic Tests."



from The Medical News http://ift.tt/1CkuHEg